Growing and treating virtual tumors using AI-designed nanoparticles

September 21 2021

Diagram showing EVONANO simulation platform for optimisation of treatment

parameters. Credit: EVONANO

The EVONANO platform allows scientists to grow virtual tumors and use artificial intelligence to automatically optimize the design of nanoparticles to treat them.

The ability to grow and treat virtual tumors is an important step towards developing new therapies for cancer. Importantly, scientists can use virtual tumors to optimize design of nanoparticle-based drugs before they are tested in the laboratory or patients.

The paper, "Evolutionary computational platform for the automatic discovery of nanocarriers for cancer treatment," is published today in the Nature journal *Computational Materials.* The paper is the result of the European project EVONANO which involves Dr. Sabine Hauert and Dr. Namid Stillman from the University of Bristol, and is led by Dr. Igor Balaz at the University of Novi Sad.

"Simulations enable us to test many treatments, very quickly, and for a large variety of tumors. We are still at the early stages of making virtual tumors, given the complex nature of the disease, but the hope is that even these simple digital tumors can help us more efficiently design nanomedicines for cancer," said Dr. Hauert.

Dr. Hauert said having the software to grow and treat virtual tumors could prove useful in the development of targeted cancer treatments.

"In the future, creating a digital twin of a patient tumor could enable the design of new nanoparticle treatments specialized for their needs, without the need for extensive trial and error or laboratory work, which is often costly and limited in its ability to quickly iterate on solutions

suited for individual patients," said Dr. Hauert.

Nanoparticle-based drugs have the potential for improved targeting of cancer cells. This is because [nanoparticles](#) are tiny vehicles that can be engineered to transport drugs to tumors. Their design changes their ability to move in the body, and correctly target cancer cells. A bioengineer might, for example, change the size, charge or material of the nanoparticle, coat the nanoparticles with molecules that make them easy to recognize by cancer cells, or load them with different drugs to kill cancer cells.

Using the new EVONANO platform, the team were able to simulate simple tumors, and more complex tumors with cancer stem cells, which are sometimes difficult to treat and lead to relapse of some cancer patients. The strategy identified nanoparticle designs that were known to work in previous research, as well as potential new strategies for nanoparticle design.

As Dr. Balaz highlights: "The tool we developed in EVONANO represents a rich platform for testing hypotheses on the efficacy of nanoparticles for various tumor scenarios. The physiological effect of tweaking nanoparticle parameters can now be simulated at the level of detail that is nearly impossible to achieve experimentally."

The challenge is then to design the right nanoparticle. Using a machine learning technique called artificial evolution, the researchers fine tune nanoparticle designs until they can treat all scenarios tested while preserving healthy cells to limit potential side-effects.

Dr. Stillman, co-lead author on the paper with Dr. Balaz, says that "this was a big team effort involving computational researchers across Europe over the past three years. I think this demonstrates the power of combining computer simulations with machine learning to find new and

exciting ways to treat cancer."

In the future, the team aims to use such a platform to bring digital twins closer to reality by using data from individual patients to grow virtual versions of their tumors, and then optimize treatments that are right for them. In the nearer term, the platform will be used to discover new nanoparticle strategies that can be tested in the laboratory. The software is open source, so there is also hope other researchers will use it to build their own AI-powered cancer nanomedicine.

"To get closer to clinical practice, in our future work we will focus on replicating tumor heterogeneity and drug resistance emergence. We believe these are the most important aspects of why cancer therapy for solid tumors often fails," said Dr. Balaz.

More information: Namid R. Stillman et al, Evolutionary computational platform for the automatic discovery of nanocarriers for cancer treatment, *npj Computational Materials* (2021). DOI: 10.1038/s41524-021-00614-5

Provided by University of Bristol